Additionally, we focus on new experimental and clinical evidence that CDK4/6 inhibition promotes key facets of antitumor immunity in the tumour microenvironment, tipping the balance in favor of the induction of an effective antitumor immune response. The gene discussed is CDK4; the disease is neoplasm.